Octaplas Pediatric Plasma Replacement Trial

Cardiac Surgery Clinical Trial

Official title:

An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02050841
• Other study ID #: LAS-212
• Status: Completed
• Phase: Phase 4
• Start date: December 2014
• Est. completion date: December 4, 2017

Study information

• Verified date: June 2020
• Source: Octapharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety, tolerability and efficacy of octaplas in pediatric patients who require replacement of multiple coagulation factors. Replacement of multiple coagulation factors in pediatric patients with acquired deficiencies due to liver disease and/or in pediatric patients requiring cardiac surgery or liver surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 4, 2017
• Est. primary completion date: December 4, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 16 Years

Eligibility

Inclusion Criteria:

1. Patient requiring liver or cardiac surgery and/or patient with liver dysfunction associated with coagulopathy in whom replacement of multiple coagulation factors is required.

2. Voluntarily given, written and signed informed consent by the patient's legal representative(s) or guardian(s). Children deemed old enough by the Investigator/institution to understand the risks and benefits of the study should also be made aware of the risks/benefits of the study and provide written assent.

3. Male or female patient = 16 years of age.

Exclusion Criteria:

1. Patient with known homozygous congenital deficiency of protein S.

2. Patient has a history of hypersensitivity reaction to blood or plasma-derived products or to any excipient of the investigational product.

3. Patient has an already known IgA (Immunoglobulin A) deficiency with documented antibodies against IgA.

4. Patient has a congenital factor deficiency or platelet disorder requiring plasma treatment.

5. Patient is currently participating in another study investigating a new drug product or another interventional clinical study that may impact coagulation factors or has participated during the last three (3) months.

6. Patient received FFP (Fresh Frozen Plasma), FP24 (Plasma frozen within 24 hours of collection) or any other plasma product other than Octaplas within the last 72 hours (cryoprecipitate and albumin are not exclusionary) prior to first Octaplas infusion.

7. Patient is on ECMO (Extracorporeal Membrane Oxygenation) when plasma is ordered by the treating physician for the first infusion episode.

8. Patient is pregnant.

9. Patient is predicted to require massive blood transfusion defined as more than 40 mL per kilogram of all blood products in a 24-hour period

10. Patient is receiving plasma exchange, therapeutic plasma exchange (TPE) or plasmapheresis.

11. Patient is a premature neonate defined as less than 37 weeks gestation.

12. Cardiac surgery patients who develop the need for plasma replacement greater than 72 hours after the end of the associated cardiac surgery and do not have coagulopathy due to hepatic dysfunction.

Related Conditions & MeSH terms

• Cardiac Surgery
• Coagulopathy
• Liver Diseases
• Liver Dysfunction
• Liver Surgery

Intervention

Biological:
• octaplas
Octaplas S/D Plasma

Locations

Country	Name	City	State
United States	Octapharma Research Site	Atlanta	Georgia
United States	Octapharma Research Site	Birmingham	Alabama
United States	Octapharma Research Site	Minneapolis	Minnesota
United States	Octapharma Research Site	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Octapharma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Drug Reactions (e.g., Allergic Reactions, TEs, TEEs (Thromboembolic Events) and Hyperfibrinolytic Events)		up to 6 days
Primary	Monitoring of Clinically Significant Changes in White Blood Cells	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Primary	Monitoring of Clinically Significant Changes in Red Blood Cells	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Primary	Monitoring of Clinically Significant Changes in Hemoglobin	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Primary	Monitoring of Clinically Significant Changes in Hematocrit	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Primary	Monitoring of Clinically Significant Changes in Mean Corpuscular Volume (MCV)	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Primary	Monitoring of Clinically Significant Changes in Mean Corpuscular Hemoglobin (MCH)	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Primary	Monitoring of Clinically Significant Changes in Mean Corpuscular Hemoglobin Concentration (MCHC)	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Primary	Monitoring of Clinically Significant Changes in Red Cell Distribution Width (RDW)	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Primary	Monitoring of Clinically Significant Changes in Platelets	Assesses Pre- and Post-infusion for Infusion Episode 1	up to 6 days
Secondary	Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: International Normalized Ratio (INR)	This hemostatic parameter is figured out in the lab and helps to diagnose a bleeding disorder or excessive clotting disorder. The change of INR before and after 1st Octaplas infusion was scrutinized by analyzing the shifts between the classifications given below.	up to 6 days
Secondary	Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Prothrombin Time (PT)	This hemostatic parameter is figured out in the lab and measures the time it takes for your blood to clot (the higher the PT the longer it takes your blood to clot). The change of PT before and after 1st Octaplas infusion was scrutinized by analyzing the shifts between the classifications given below.	up to 6 days
Secondary	Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Thromboelastography (TEG) or Thromboelastometry (ROTEM).	TEG and ROTEM are methods of testing the efficiency of blood coagulation. The results were compared by looking at potential trends from TEG and ROTEM between pre-infusion vs post-infusion time points.	up to 6 days
Secondary	Number of Participants With Clinically Significant Changes in Hemostatic Parameters as Measured by the Following: Activated Partial Thromboplastin Time (aPTT)	aPTT measures the length of time (in seconds) that it takes for clotting to occur in a test cube. The higher the number of seconds the longer it takes the blood to clot. The changes between pre - and post infusion were analyzed	up to 6 days
Secondary	Volume (Dose in mL/kg) of Octaplas Used Per Infusion Episode for Each Patient.	Normal infusion: Replacement of multiple clotting factors Bypass priming: Limit hemodilution and reduce transfusion requirements Bypass warming up: Rewarm patients suffering from hypothermia during the surgery process	up to 6 days
Secondary	Medically Significant Changes in Blood Pressure		up to 6 days
Secondary	Medically Significant Changes in Heart Rate		up to 6 days
Secondary	Medically Significant Changes in Respiratory Rate		up to 6 days
Secondary	Medically Significant Changes in Oxygen Saturation		up to 6 days
Secondary	Medically Significant Changes in Body Temperature		up to 6 days
Secondary	Count of Investigator's Assessment of Overall Safety Observed for Patients by Category (Assessed to Have Overall Safety of 'Excellent', Assessed to Have Overall Safety of 'Moderate', Assessed to Have Overall Safety of 'Poor')		up to 6 days